Takeda Pharmaceutical (TYO:4502) and BioSurfaces said today that the two companies inked a deal to develop novel medical devices intended to treat patients with gastrointestinal diseases.
The deal brings together Takeda’s experience in the gastroenterology space and BioSurfaces’ method of developing nanomaterials from FDA-approved polymers for medical implants and drug-delivery devices. Financial terms of the deal were not disclosed.
Get the full story at our sister site, Drug Delivery Business News.
The post Takeda, BioSurfaces collab on GI drug-delivery devices appeared first on MassDevice.
from MassDevice http://ift.tt/2uTCTi1
Cap comentari:
Publica un comentari a l'entrada